Loading...

Terence Friedlander, MD

TitleAssociate Professor
SchoolUCSF School of Medicine
DepartmentMedicine
Address550 16th. Street
San Francisco CA 94158
Phone415-514-6380
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown University, ProvidenceBA1999Biology
    New York University Medical School, New YorkMD2003Medicine
    University of California, San Francisco, San FranciscoInternal Medicine Internship2004Medicine
    University of California, San Francisco, San FranciscoInternal Medicine Residency2004Medicine
    Utrecht University, NetherlandsMA2007Medical Ethics
    University of California, San Francisco, San FranciscoFellowship2010Hematology/Oncology
    University of California, San Francisco, San FranciscoChief Fellow2010Hematology/Oncology
    University of California, San Francisco, San FranciscoFellowship2011Urologic Oncology
    Collapse Awards and Honors
    NYU Medical School2000  - 2000Herman Goldman Scholarship
    NYU Medical School2003  - 2003Spiegel Award for Academic Excellence
    NYU Medical School2003  - 2003Alpha Omega Alpha
    NYU Medical School2003  - 2003Medical Degree with Honors
    Netherlands-America Foundation2006  - 2006 Fulbright Scholarship in Medical Ethics
    American Society of Clinical Oncology2010  - 2010Young Investigator Award
    Prostate Cancer Foundation2012  - 2012Young Investigator Award
    United States Department of Defense2012  - 2012 Physician Research Training Award
    Advances in Circulating Tumor Cells Conference Foundation2012  - 2012Travel Award
    UCSF Annual Prostate Cancer Retreat2013  - 2013Poster Award

    Collapse Overview 
    Collapse Overview
    My research is focused on understanding the biology of advanced prostate and bladder cancers and developing novel therapeutics to treat these diseases. Specifically I am interested in understanding the genomics of advanced prostate cancer through the acquisition of castration-resistant biopsies and circulating tumor cells, then using genomic techniques to identify pathways and mechanisms of treatment resistance.

    Similarly I am interested in developing novel chemotherapeutic and immunotherapeutic strategies to treat both localized and advanced bladder cancer. I also collaborate with basic scientists at UCSF to use circulating tumor cells both as biomarkers of response and resistance to therapy in prostate and bladder cancer, and also as a tool to investigate the basic biology of these tumors.


    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Aug 17; e172411. PMID: 28817753.
      View in: PubMed
    2. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Jun 03. PMID: 28655452.
      View in: PubMed
    3. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 Mar 17. PMID: 28314838.
      View in: PubMed
    4. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Feb 01. PMID: 28161323.
      View in: PubMed
    5. Friedlander TW, Pritchard CC, Beltran H. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. Am Soc Clin Oncol Educ Book. 2017; 37:358-369. PMID: 28561699.
      View in: PubMed
    6. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander T, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 Sep 29. PMID: 27688020.
      View in: PubMed
    7. Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, Edwards M, Paz R, Lindquist K, Graf R, Jendrisak A, Louw J, Dugan L, Baird S, Wang Y, Dittamore R, Paris PL. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 2016 Sep 22; 16(1):744. PMID: 27658492.
      View in: PubMed
    8. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 Sep 28; 380(1):144-52. PMID: 27343980.
      View in: PubMed
    9. Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. Urol Oncol. 2016 Aug; 34(8):356-67. PMID: 26706121.
      View in: PubMed
    10. Anantharaman A, Friedlander T. A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2015 Dec; 68(6):946-8. PMID: 26278804.
      View in: PubMed
    11. Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, Premasekharan G, Tran T, Fu C, Ionescu-Zanetti C, Schwartz M, Fan A, Paris P. Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. J Urol. 2015 Sep; 194(3):790-8. PMID: 25912492.
      View in: PubMed
    12. Anantharaman A, Friedlander T. The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks. Oncology (Williston Park). 2015 Jan; 29(1):67-8. PMID: 25592211.
      View in: PubMed
    13. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander T, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. PMID: 25336698; PMCID: PMC4277885 [Available on 12/15/15].
    14. Friedlander T, Fong L. The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1104-6. PMID: 24616311.
      View in: PubMed
    15. Friedlander T, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2014 May 15; 134(10):2284-93. PMID: 24166007.
      View in: PubMed
    16. Friedlander T, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2014 Jun; 142(3):271-80. PMID: 24362084.
      View in: PubMed
    17. Friedlander T, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012 Feb 1; 72(3):616-25. PMID: 22158653.
      View in: PubMed
    18. Friedlander T, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. PMID: 21971890.
      View in: PubMed
    19. Friedlander T, Ryan CJ. Editorial comment. J Urol. 2010 Nov; 184(5):1976. PMID: 20884031.
      View in: PubMed
    20. Friedlander T, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. PMID: 20884247.
      View in: PubMed
    21. Friedlander T, Ryan CJ. Novel hormonal approaches in prostate cancer. Curr Oncol Rep. 2009 May; 11(3):227-34. PMID: 19336015.
      View in: PubMed
    Terence's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP